180 related articles for article (PubMed ID: 35942695)
21. [Efficacy and safety of bulevirtide in patients with chronic hepatitis D and compensated cirrhosis].
Bogomolov PO; Ivashkin VT; Bueverov AO; Maev IV; Sagalova OI; Sleptsova SS; Yushuk ND; Gusev DA; Zhdanov KV; Chulanov VP
Ter Arkh; 2021 Nov; 93(11):1290-1299. PubMed ID: 36286651
[TBL] [Abstract][Full Text] [Related]
22. Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta.
Deterding K; Wedemeyer H
AIDS Rev; 2019; 21(3):126-134. PubMed ID: 31532397
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
[TBL] [Abstract][Full Text] [Related]
24. New therapies for hepatitis delta virus infection.
Loureiro D; Castelnau C; Tout I; Boyer N; Narguet S; Menasria Benazzouz S; Louis Z; Pons-Kerjean N; Giuly N; Marcellin P; Mansouri A; Asselah T
Liver Int; 2021 Jun; 41 Suppl 1():30-37. PubMed ID: 34155804
[TBL] [Abstract][Full Text] [Related]
25. Real-life experiences with bulevirtide for the treatment of hepatitis delta-48 weeks data from a German centre.
Zöllner C; Hofmann J; Lutz K; Tacke F; Demir M
Liver Int; 2022 Nov; 42(11):2403-2407. PubMed ID: 36004554
[TBL] [Abstract][Full Text] [Related]
26. Modelling HDV kinetics under the entry inhibitor bulevirtide suggests the existence of two HDV-infected cell populations.
Shekhtman L; Cotler SJ; Degasperi E; Anolli MP; Uceda Renteria SC; Sambarino D; Borghi M; Perbellini R; Facchetti F; Ceriotti F; Lampertico P; Dahari H
JHEP Rep; 2024 Feb; 6(2):100966. PubMed ID: 38274491
[TBL] [Abstract][Full Text] [Related]
27. Hepatitis D virus: Improving virological knowledge to develop new treatments.
Khalfi P; Kennedy PT; Majzoub K; Asselah T
Antiviral Res; 2023 Jan; 209():105461. PubMed ID: 36396025
[TBL] [Abstract][Full Text] [Related]
28. Bulevirtide for HBV and HDV infections.
Yardeni D; Koh C
Drugs Today (Barc); 2021 Jul; 57(7):433-448. PubMed ID: 34268531
[TBL] [Abstract][Full Text] [Related]
29. Sodium taurocholate cotransporting polypeptide (NTCP) polymorphisms may influence HDV RNA load and early response to bulevirtide.
Toniutto P; Falleti E; Cmet S; Cussigh A; Degasperi E; Anolli MP; Sambarino D; Facchetti F; Borghi M; Perbellini R; Monico S; Lampertico P
J Hepatol; 2024 Jun; ():. PubMed ID: 38901675
[TBL] [Abstract][Full Text] [Related]
30. Future treatments for hepatitis delta virus infection.
Asselah T; Loureiro D; Tout I; Castelnau C; Boyer N; Marcellin P; Mansouri A
Liver Int; 2020 Feb; 40 Suppl 1():54-60. PubMed ID: 32077603
[TBL] [Abstract][Full Text] [Related]
31. A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D.
Wedemeyer H; Aleman S; Brunetto MR; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova T; Berger A; Manuilov D; Suri V; An Q; Da B; Flaherty J; Osinusi A; Liu Y; Merle U; Schulze Zur Wiesch J; Zeuzem S; Ciesek S; Cornberg M; Lampertico P;
N Engl J Med; 2023 Jul; 389(1):22-32. PubMed ID: 37345876
[TBL] [Abstract][Full Text] [Related]
32. "Real world" efficacy of bulevirtide in HBV/HDV-related cirrhosis including people living with HIV: Results from the compassionate use programme at INMI Spallanzani in Rome, Italy.
Visco Comandini U; De Santis E; De Maria F; Lionetti R; Taibi C; Montalbano M; Rianda A; Piccolo P; De Ponte C; Mazzotta S; Caioli A; Garbuglia AR; Maggi F; D'Offizi G
HIV Med; 2023 Oct; 24(10):1075-1082. PubMed ID: 37287427
[TBL] [Abstract][Full Text] [Related]
33. Quantification of serum HDV RNA by Robogene 2.0 in HDV patients is significantly influenced by the extraction methods.
Anolli MP; Renteria SU; Degasperi E; Borghi M; Facchetti F; Sambarino D; Perbellini R; Monico S; Ceriotti F; Lampertico P
Liver Int; 2024 Mar; 44(3):831-837. PubMed ID: 38247385
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022.
Lampertico P; Degasperi E; Sandmann L; Wedemeyer H;
JHEP Rep; 2023 Sep; 5(9):100818. PubMed ID: 37593170
[TBL] [Abstract][Full Text] [Related]
35. Beyond bulevirtide: Alternative therapeutic options for the management of hepatitis delta virus.
Asselah T
J Viral Hepat; 2023 Apr; 30 Suppl 1():33-38. PubMed ID: 36529713
[TBL] [Abstract][Full Text] [Related]
36. Antiviral treatment and liver-related complications in hepatitis delta.
Wranke A; Serrano BC; Heidrich B; Kirschner J; Bremer B; Lehmann P; Hardtke S; Deterding K; Port K; Westphal M; Manns MP; Cornberg M; Wedemeyer H
Hepatology; 2017 Feb; 65(2):414-425. PubMed ID: 27770553
[TBL] [Abstract][Full Text] [Related]
37. New Treatments for Chronic Hepatitis B Virus/Hepatitis D Virus Infection.
Sandmann L; Wedemeyer H
Clin Liver Dis; 2021 Nov; 25(4):831-839. PubMed ID: 34593156
[TBL] [Abstract][Full Text] [Related]
38. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.
Wedemeyer H; Yurdaydin C; Hardtke S; Caruntu FA; Curescu MG; Yalcin K; Akarca US; Gürel S; Zeuzem S; Erhardt A; Lüth S; Papatheodoridis GV; Keskin O; Port K; Radu M; Celen MK; Idilman R; Weber K; Stift J; Wittkop U; Heidrich B; Mederacke I; von der Leyen H; Dienes HP; Cornberg M; Koch A; Manns MP;
Lancet Infect Dis; 2019 Mar; 19(3):275-286. PubMed ID: 30833068
[TBL] [Abstract][Full Text] [Related]
39. The effect of twelve weeks of treatment with ezetimibe on HDV RNA level in patients with chronic hepatitis D.
Abbas Z; Saad M; Asim M; Abbas M; Samejo SA
Turk J Gastroenterol; 2020 Feb; 31(2):136-141. PubMed ID: 32141822
[TBL] [Abstract][Full Text] [Related]
40. Treating hepatitis D with bulevirtide - Real-world experience from 114 patients.
Dietz-Fricke C; Tacke F; Zöllner C; Demir M; Schmidt HH; Schramm C; Willuweit K; Lange CM; Weber S; Denk G; Berg CP; Grottenthaler JM; Merle U; Olkus A; Zeuzem S; Sprinzl K; Berg T; van Bömmel F; Wiegand J; Herta T; Seufferlein T; Zizer E; Dikopoulos N; Thimme R; Neumann-Haefelin C; Galle PR; Sprinzl M; Lohse AW; Schulze Zur Wiesch J; Kempski J; Geier A; Reiter FP; Schlevogt B; Gödiker J; Hofmann WP; Buggisch P; Kahlhöfer J; Port K; Maasoumy B; Cornberg M; Wedemeyer H; Deterding K
JHEP Rep; 2023 Apr; 5(4):100686. PubMed ID: 37025462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
